Breast Cancer Drug Wins Approval Despite Rejection by Agency Advisors

(MedPage Today) -- The FDA on Friday granted accelerated approval to camizestrant (Etcamah) for treating hormone receptor-positive/HER2-negative breast cancer at the first sign of ESR1 resistance mutations during first-line treatment. Camizestrant...